Gilead and Merck Reports Phase II Data Showing that Switching to a Once-Weekly Oral Combination of Islatravir and Lenacapavir Maintained Viral Suppression in Adults Through 48 Weeks
Gilead Sciences, Inc. and Merck have shared new findings from a Phase II clinical trial assessing the experimental combination of islatravir, a novel nucleoside reverse transcriptase translocation inhibitor, and lenacapavir, a pioneering HIV-1 capsid inhibitor. These significant results were presented during an oral session at IDWeek 2024, held in Los Angeles and online from October 16-19.
At 48 weeks, the new investigational combination achieved a high viral suppression rate (n=49; ...
